Skip to main content
. Author manuscript; available in PMC: 2020 Aug 5.
Published in final edited form as: Clin Cancer Res. 2017 May 22;23(17):5091–5100. doi: 10.1158/1078-0432.CCR-16-2540

Figure 5. Performance of an airway biomarker in detecting the presence and progression of premalignant lesions.

Figure 5.

The ROC curves demonstrate the biomarker performance. (A) ROC curve (AUC=0.92) showing biomarker performance based on predictions of the presence of PMLs in the validation samples (n=17), black line. Shuffling of class labels (n=100 permutations) produced an average ROC curve (dotted line) with a significantly lower AUC (p<<0.001). (B) ROC curve (AUC=0.75) showing biomarker performance based on changes in biomarker score over time in detecting PML regression or stable/progression.